Skip to content
Screener

DBV Technologies DBVT Total Liabilities & Equity

Total Liabilities & Equity at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$490.78M+288%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$363.79M-30.1%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$141.13M+38.0%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$782.35M+13.0%
Alumis Inc. logo
Alumis Inc.ALMS
$671.59M+157%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$763.27M+198%

Other financials

Income statement

See full
Revenue$700.0K-53.3%
Operating income-$50.6M-23.1%
Net income-$50.4M-20.3%
EPS (diluted)-$0.12+61.3%

Balance sheet

See full
Cash & equivalents$174.9M+69.5%
Total debt$7.7M+0.1%
Total equity$160.4M+86.1%
Total assets$223.2M+55.6%

Cash flow

See full
Operating cash flow-$52.6M-55.2%
CapEx$400.0K
Free cash flow-$53.0M-56.3%

Valuation

See full
Market cap$847.16M+218%
Enterprise value$679.96M+297%
P/S168.8×+100×

Profitability

See full
Operating margin-3,543.1%+523pp
Net margin-3,506.5%+442pp
FCF margin-3,399.3%+3,268pp

Returns & leverage

See full
Return on equity-142.7%-5.0pp
Debt / equity0.0×
Current ratio3.7×+1.3×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: DBV Technologies’s 10-Q, filed July 16, 2026.

Filed
Jul 16, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-048453
Line itemNoteJune 30, 2026December 31, 2025
Ordinary shares, €0.10 par value; 296,061,497 and 235,670,864 shares authorized, and issued as of June 30, 2026 and December 31, 2025, respectively,34.026.9
Additional paid-in capital408.3541.3
Treasury stock, 146,321 and 74,680 ordinary shares as of June 30, 2026 and December 31, 2025, respectively, at cost(0.8)(0.8)
Accumulated deficit(270.3)(393.1)
Accumulated other comprehensive income0.50.5
Accumulated currency translation effect(11.2)(5.9)
Total Shareholders’ equity160.4168.8
Total Liabilities and Shareholder's equity223.2233.7

Item 1C. Condensed Consolidated Statements of Financial Position (Unaudited) as of

FAQ

What is DBV Technologies's total liabilities & equity?
DBV Technologies (DBVT) reported total liabilities & equity of $223.2M in Q2 2026.
How has DBV Technologies's total liabilities & equity changed year-over-year?
DBV Technologies's total liabilities & equity increased by 55.6% year-over-year, from $143.43M to $223.2M.
What is the long-term trend for DBV Technologies's total liabilities & equity?
Over 5 years (2020 to 2025), DBV Technologies's total liabilities & equity has grown at a -3.0% compound annual growth rate (CAGR), from $272.25M to $233.7M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about DBV Technologies's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude